标题：恶性黑色素瘤的免疫治疗进展

      作者：严森林 综述 赵颖海 审校    广东医科大学病理系，广东 湛江 524023

      卷次： 2021年32卷3期

      【摘要】 恶性黑色素瘤(malignant melanoma)是一种多发生于皮肤的高度恶性肿瘤，发病率正逐步升高，为皮肤的首位致死性疾病。常规的治疗方法包括手术、化疗、放疗、热疗及免疫治疗等。目前用于恶性黑色素瘤免疫和靶向治疗的药物包括细胞因子、激酶抑制剂、免疫检查点抑制剂等，本文对上述药物的应用、疗效及安全性等进行综述。
      【关键词】 黑色素瘤；细胞因子；激酶抑制剂；免疫检查点抑制剂；免疫相关不良事件
      【中图分类号】 R739.5 【文献标识码】 A 【文章编号】 1003—6350（2021）03—0354—05

Research progress in immunotherapy of malignant melanoma.
YAN Sen-lin, ZHAO Ying-hai. Department ofPathology, Guangdong Medical University, Zhanjiang 524023, Guangdong, CHINA【Abstract】 Malignant melanoma is a highly malignant tumor that often occurs in the skin, and its incidence isgradually increasing. It is the first fatal disease of the skin. Conventional treatment methods include surgery, chemothera-py, radiotherapy, hyperthermia and immunotherapy, etc. The drugs currently used for immune and targeted therapy of ma-lignant melanoma include cytokines, kinase inhibitors, immune checkpoint inhibitors, etc. This article reviews the appli-cation, efficacy and safety of these drugs.
      【Key words】 Melanoma; Cytokines; Kinase inhibitors; Immune checkpoint inhibitors; Immune-related adverseevents·综述·doi:10.3969/j.issn.1003-6350.2021.03.023基金项目：广东省湛江市第二批非资助科技攻关计划项目(编号：2015B01082)